Drug Trial Radar · NCT04634877
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
990
Planned (sponsor's estimate)
Start
Jan 10, 2021
Primary completion
Nov 20, 2026
Study completion Nov 20, 2026
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- European Network of Gynaecological Oncological Trial Groups (ENGOT); Gynecologic Oncology Group
- First posted
- Nov 18, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare pembrolizumab + adjuvant chemotherapy with placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to disease-free survival (DFS) as assessed radiographically by the investigator or by histopathologic confirmation of suspected disease recurrence, and with respect to overall survival (OS). The primary hypotheses are that pembrolizumab + adjuvant chemotherapy is superior to placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to DFS as assessed radiographically by the investigator or by histopathologic confirmation of suspected disease recurrence, and with respect to OS.
Conditions
- Endometrial Neoplasms
Interventions
PembrolizumabBiological
IV infusion
CarboplatinDrug
IV infusion
PaclitaxelDrug
IV infusion
Placebo for pembrolizumabDrug
IV infusion
DocetaxelDrug
IV infusion docetaxel 75 mg/m\^2 Q3W or 25 mg/m2 QW may be given in place of paclitaxel following sponsor consultation if a participant experiences severe hypersensitivity to paclitaxel or an adverse event requiring discontinuation of paclitaxel.
CisplatinDrug
Cisplatin 75 mg/m\^2 IV infusion Q3W may be given in place of carboplatin following sponsor consultation if a participant experiences severe hypersensitivity to carboplatin or an adverse event requiring discontinuation of carboplatin.
External Beam Radiotherapy (EBRT)Radiation
≥4500 cGY given according to local practice, at the discretion of the investigator
Cisplatin (as radiosensitizer)Drug
If a participant receives external beam radiotherapy (EBRT), then cisplatin 50 mg/m\^2 IV infusion may be administered as a radiosensitizer at the discretion of the investigator, on days 1 and 29
BrachytherapyRadiation
Given according to local practice, at the discretion of the investigator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-Free Survival (DFS) as Assessed Radiographically by Investigator or by Histopathologic Confirmation of Suspected Disease RecurrenceTime frame: Up to approximately 42 months
- Overall Survival (OS)Time frame: Up to approximately 54 months
Locations
231 sites in 28 countries. Site status is shown where the registry gives one.
University of Alabama - Birmingham ( Site 3061)
Birmingham, Alabama
University of South Alabama, Mitchell Cancer Institute ( Site 3058)
Mobile, Alabama
HonorHealth Research Institute - Biltmore ( Site 3043)
Phoenix, Arizona
Arizona Oncology Associates PC- HOPE ( Site 3049)
Tucson, Arizona
UCSD Moores Cancer Center ( Site 3053)
La Jolla, California
University Of Colorado ( Site 3051)
Aurora, Colorado
Smilow Cancer Hospital at Yale New Haven ( Site 3070)
New Haven, Connecticut
Mount Sinai Cancer Center ( Site 3081)
Miami Beach, Florida
Northside Hospital ( Site 3036)
Atlanta, Georgia
Northwestern Memorial Hospital ( Site 3044)
Chicago, Illinois
Parkview Cancer Institute ( Site 3067)
Fort Wayne, Indiana
Indiana University Melvin and Bren Simon Cancer Center ( Site 3071)
Indianapolis, Indiana
University of Iowa Hospital and Clinics ( Site 3046)
Iowa City, Iowa
Norton Cancer Institute - St. Matthews ( Site 3056)
Louisville, Kentucky
WK Physicians Network/Gynecologic Oncology Associates ( Site 3047)
Shreveport, Louisiana
University of Massachusetts Medical School-Division of Gynecologic Oncology ( Site 3037)
Worcester, Massachusetts
Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 3076)
Mineola, New York
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 3042)
New York, New York
Montefiore Medical Center ( Site 3065)
The Bronx, New York
Duke Cancer Center ( Site 3072)
Durham, North Carolina
Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 3080)
Fargo, North Dakota
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 3066)
Columbus, Ohio
Legacy Good Samaritan Medical Center ( Site 3033)
Portland, Oregon
Sidney Kimmel Cancer Center - Jefferson Health ( Site 3078)
Philadelphia, Pennsylvania
AHN West Penn Hospital ( Site 3060)
Pittsburgh, Pennsylvania
Abington Hospital - Asplundh Cancer Center ( Site 3073)
Willow Grove, Pennsylvania
Sanford Gynecology Oncology ( Site 3045)
Sioux Falls, South Dakota
UT Southwestern Medical Center ( Site 3063)
Dallas, Texas
VCU Massey Cancer Center ( Site 3068)
Richmond, Virginia
IDIM - Instituto de Diagnóstico e Investigaciones Metabólicas ( Site 1010)
Buenos Aires, Argentina
Hospital Aleman ( Site 1001)
Buenos Aires, Argentina
Centro Oncologico Riojano Integral ( Site 1007)
La Rioja, Argentina
Centro de Oncología e Investigación de Buenos Aires ( Site 1005)
Berazategui, Buenos Aires, Argentina
IDIM Instituto de Diagnostico e Investigaciones Metabolicas ( Site 1006)
CABA, Buenos Aires, Argentina
CEMIC ( Site 1009)
CABA, Buenos Aires, Argentina
Hospital Britanico de Buenos Aires ( Site 1002)
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Instituto de Investigaciones Clinicas Mar del Plata ( Site 1003)
Mar del Plata, Buenos Aires, Argentina
Instituto de Oncologia de Rosario ( Site 1004)
Rosario, Santa Fe Province, Argentina
Medizinische Universitat Graz ( Site 2004)
Graz, Styria, Austria
Medizinische Universitaet Innsbruck ( Site 2001)
Innsbruck, Tyrol, Austria
Showing 40 of 231 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.